Evidence map›Paper›PMID 38592428›Full record

ArticleMolecular and cellular biochemistry2024

STING agonist, SMA-2, inhibits clear cell renal cell carcinoma through improving tumor microenvironment.

Wei Wang, Fengqing Zhang, Yan Hu, Guangming Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wei WangDepartment of Urology, Tianjin First Central Hospital, NO.24 Fukang Road, Nankai District, Tianjin, 300192, People's Republic of China.
Fengqing ZhangDepartment of Surgery, Tianjin Prevention and Treatment Center for Occupational Diseases, Hedong District, Tianjin, 300011, People's Republic of China.
Yan HuClinical Lab, Tianjin Rehabilitation Recuperation Center, Nankai District, Tianjin, 300381, People's Republic of China.
Guangming LiuDepartment of Urology, Tianjin First Central Hospital, NO.24 Fukang Road, Nankai District, Tianjin, 300192, People's Republic of China. 5020230031@nankai.edu.cn.

Funding

Tianjin Key Medical Discipline(Specialty) Construction Project TJYXZDXK-073C
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most prevalent and lethal subtype of kidney cancer, patients with ccRCC usually have very poor prognosis and short survival. Therefore, it is urgent to develop more effective therapeutics or medications to suppress ccRCC progression. Here, we demonstrated that STING agonist, MSA-2 significantly inhibits tumor progress and prolongs the survival of ccRCC mice by promoting cytokines secretion. Moreover, MSA-2 triggered the trafficking and infiltration of CD8

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMembrane ProteinsTumor MicroenvironmentAnimalsCD8-Positive T-LymphocytesCell Line, TumorHumansMiceSTING ProteinMembrane ProteinsSting1 protein, mouseSTING ProteinCytokineImmune therapySTING agonistTumor microenvironmentTumor progression

Identifiers

PMID38592428
PMCPMC11255009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.